|
|
|
Polymorphism of pharmaceutical molecules: perspectives
on nucleation |
| Jie LU,Zhen LI,Xiaolin JIANG, |
| School of Chemical &
Material Engineering, Jiangnan University, Wuxi 214122, China; |
|
|
|
|
Abstract Polymorphism is a widespread phenomenon observed in more than half of all drug substances. Various polymorphs frequently possess different physical, chemical, mechanical and thermal properties that can profoundly affect the bioavailability, stability and other performance characteristics of the drug. Accordingly, the elucidation of the relationship between the particular polymorph of a pharmaceutical molecule and its functional properties is crucial to select the most suitable polymorph of the pharmaceutical molecule for development into a drug product. This review briefly introduces recent advances in the discovery and control of the polymorphs of pharmaceutical molecules, in terms of the enhancement of the selective nucleation of a particular polymorph. In the light of this, some cases discussed in the following is to be considered controversial.
|
|
Issue Date: 05 March 2010
|
|
|
Wu H. An analysis on the production and sale of China’s pharmaceuticalindustry. Chinese J Pharm, 2007, 38(4): A27–A34
|
|
Shekunov B Y, York P. Crystallization processesin pharmaceutical technology and drug delivery design. J Cryst Growth, 2000, 211: 122–136
doi: 10.1016/S0022-0248(99)00819-2
|
|
Morissette S L, Almarsson Ö, Peterson M L, Remenar J F, Read M J, Lemmo A V, Ellis S, Cima M J, Gardner C R. High-throughput crystallization: polymorphs, salts, co-crystals andsolvates of pharmaceutical solids. AdvDrug Deliv Rev, 2004, 56: 275–300
doi: 10.1016/j.addr.2003.10.020
|
|
Datta S, Grant D J W. Crystal structures of drugs:advances in determination, prediction and engineering. Nat Rev Drug Discov, 2004, 3: 42–57
doi: 10.1038/nrd1280
|
|
Sirota N N. Certain problems of polymorphism (I). Cryst Res Technol, 1982, 17: 661–691
doi: 10.1002/crat.2170170602
|
|
Doherty C, York P. Frusemide crystal forms—solid-stateand physicochemical analyses. Int J Pharm, 1988, 47: 141–155
doi: 10.1016/0378-5173(88)90225-6
|
|
Lu J, Rohani S. Polymorphic crystallizationand transformation of the anti-viral/HIV drug stavudine. Org Process Res Dev, 2009, 13: 1262–1268
doi: 10.1021/op900004c
|
|
Rodríguez-Caabeiro F, Criado-Fornelio A, Jimenez-Gonzalez A, Guzman L, Igual A, Perez A, Pujol M. Experimentalchemotherapy and toxicity in mice of three mebendazole polymorphicforms. Chemotherapy, 1987, 33: 266–271
doi: 10.1159/000238506
|
|
Swanepoel E, Liebenberg W, de Villiers M M. Quality evaluation of generic drugs bydissolution test: changing the USP dissolution medium to distinguishbetween active and non-active mebendazole polymorphs. Eur J Pharm Biopharm, 2003, 55: 345–349
doi: 10.1016/S0939-6411(03)00004-3
|
|
Sun C, Grant D J W. Influence of crystal structureon the tableting properties of sulfamerazine polymorphs. Pharm Res, 2001, 18: 274–280
doi: 10.1023/A:1011038526805
|
|
Mirmehrabi M, Rohani S. An approach to solvent screeningfor crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci, 2005, 94: 1560–1576
doi: 10.1002/jps.20371
|
|
Aakeroy C B, Fasulo M E, Desper J. Cocrystal or salt: does it really matter? Mol Pharm, 2007, 4: 317–322
doi: 10.1021/mp060126o
|
|
Aitipamula S, Chow P S, Tan R B H. Dimorphs of a 1:1 cocrystal of ethenzamide and saccharin:solid-state grinding methods result in metastable polymorph. Cryst Eng Comm, 2009, 11: 889–895
doi: 10.1039/b821373a
|
|
Bernstein J, Hagler A T. Conformational polymorphism—theinfluence of crystal structure on molecular conformation. J Am Chem Soc, 1978, 100: 673–681
doi: 10.1021/ja00471a001
|
|
Bernstein J, Davey R J, Henck J O. Concomitant polymorphs. AngewChem Int Ed, 1999, 38: 3440–3461
doi: 10.1002/(SICI)1521-3773(19991203)38:23<3440::AID-ANIE3440>3.0.CO;2-#
|
|
Datta S, Grant D J W. Effect of supersaturationon the crystallization of phenylbutazone polymorphs. Cryst Res Technol, 2005, 40: 233–242
doi: 10.1002/crat.200410331
|
|
Gracin S, Rasmuson ÅC. Polymorphismand crystallization of p acid. Cryst Growth Des, 2004, 4: 1013–1023
doi: 10.1021/cg049954h
|
|
Gu C H, Young V, Grant D J W. Polymorph screening: influence of solvents on the rateof solvent-mediated polymorphic transformation. J Pharm Sci, 2001, 90: 1878–1890
doi: 10.1002/jps.1137
|
|
Weissbuch I, Lahav M, Leiserowitz L. Toward stereochentical control, monitoring, and understandingof crystal nucleation. Cryst Growth Des, 2002, 3: 125–150
doi: 10.1021/cg0200560
|
|
Davey R J, Allen K, Blagden N, Cross W I, Lieberman H F, Quayle M J, Righini S, Seton L, Tiddy G J T. Crystal engineering—nucleation, the key step. Cryst Eng Commun, 2002, 4: 257–264
doi: 10.1039/b203521a
|
|
Khoshkhoo S, Anwar J. Crystallization of polymorphs—theeffect of solvent. J Phys D-Appl Phys, 1993, 26: B90–B93
doi: 10.1088/0022-3727/26/8B/013
|
|
Tao J, Jones K J, Yu L. Cross-nucleation between D-mannitol polymorphs in seededcrystallization. Cryst Growth Des, 2007, 7: 2410–2414
doi: 10.1021/cg070387i
|
|
Beckmann W, Otto W, Budde U. Crystallization of the stable polymorph of hydroxytriendione:seeding process and effects of purity. Org Process Res Dev, 2001, 5: 387–392
doi: 10.1021/op010013c
|
|
Tanaka S, Ataka M, Kubota T, Soga T, Homma K, Lee W C, Tanokura M. The effect of amphiphilicadditives on the growth and morphology of aspergillus niger acid proteinasea crystals. J Cryst Growth, 2002, 234: 247–254
doi: 10.1016/S0022-0248(01)01657-8
|
|
Rodríguez-Spong B, Price C P, Jayasankar A, Matzger A J, Rodríguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecularperspective. Adv Drug Deliv Rev, 2004, 56: 241–274
doi: 10.1016/j.addr.2003.10.005
|
|
Lee E H, Boerrigter S X M, Rumondor A C F, Chamarthy S P, Byrn S R.Formation and solid-statecharacterization of a salt-induced metastable polymorph of flufenamicacid. Cryst Growth Des, 2008, 8: 91–97
doi: 10.1021/cg7008607
|
|
Yang X, Lu J, Wang X J, Ching C B. Effect ofsodium chloride on the nucleation and polymorphic transformation ofglycine. J Cryst Growth, 2008, 310: 604–611
doi: 10.1016/j.jcrysgro.2007.11.072
|
|
Lang M D, Grzesiak A L, Matzger A J. The use of polymer heteronuclei for crystalline polymorphselection. J Am Chem Soc, 2002, 124: 14834–14835
doi: 10.1021/ja0286526
|
|
Bonafede S J, Ward M D. Selective nucleation andgrowth of an organic polymorph by ledge-directed epitaxy on a molecular-crystalsubstrate. J Am Chem Soc, 1995, 117: 7853–7861
doi: 10.1021/ja00135a001
|
|
Hiremath R, Varney S W, Swift J A. Selective growth of a less stable polymorph of 2-iodo-4-nitroanilineon a self-assembled monolayer template. Chem Commun, 2004, 2676–2677
doi: 10.1039/b411649f
|
|
Dressler D H, Mastai Y. Controlling polymorphismby crystallization on self-assembled multilayers. Cryst Growth Des, 2007, 126: 847–850
doi: 10.1021/cg0606287
|
|
Ha J M, Wolf J H, Hillmyer M A, Ward M D. Polymorphselectivity under nanoscopic confinement. J Am Chem Soc, 2004, 126: 3382–3383
doi: 10.1021/ja049724r
|
|
Garetz B A, Aber J E, Goddard N L, Young R G, Myerson A S. Nonphotochemical, polarization-dependent,laser-induced nucleation in supersaturated aqueous urea solutions. Phys Rev Lett, 1996, 77: 3475–3476
doi: 10.1103/PhysRevLett.77.3475
|
|
Zaccaro J, Matic J, Myerson A S, Garetz B A. Nonphotochemical,laser-induced nucleation of supersaturated aqueous glycine producesunexpected gamma-polymorph. Cryst GrowthDes, 2001, 1: 5–8
doi: 10.1021/cg0055171
|
|
Llinàs A, Goodman J M. Polymorph control: past,present and future. Drug Discov Today, 2008, 13(5–6): 198–210
doi: 10.1016/j.drudis.2007.11.006
|
|
Di Profio G, Tucci S, Curcio E, Drioli E. Selectiveglycine polymorph crystallization by using microporous membranes. Cryst Growth Des, 2007, 7: 526–530
doi: 10.1021/cg0605990
|
|
Liu Y X, Wang X J, Lu J, Ching C B. Influenceof the roughness, topography and physicochemical properties of chemicallymodified surfaces on the heterogeneous nucleation of protein crystals. J Phys Chem B, 2007, 111(50): 13971–13978
doi: 10.1021/jp0741612
|
|
Gardner C R, Almarsson Ö, Chen H, Morissette S L, Peterson M L, Zhang Z, Wang S, Lemmo A V, Gonzales-Zugasti J, Monagle J, Marchionna J, Ellis S J, McNulty C, Johnson A, Levinson D, Cima M J. Application of high-throughput technologies to drug substanceand drug product development. Comput ChemEng, 2004, 28: 943–953
doi: 10.1016/j.compchemeng.2003.09.028
|
|
Lu J, Rohani S, Polymorphism and crystallizationof active pharmaceutical ingredients (APIs). Curr Med Chem, 2009, 16: 884–905
doi: 10.2174/092986709787549299
|
|
Gavezzotti A. Computer simulations of organic solids and their liquid-state precursors. Faraday Discuss, 1997, 106: 63–77
doi: 10.1039/a701436h
|
|
Gavezzotti A. Ten years of experience in polymorph prediction: what next? Cryst Eng Comm, 2002, 4: 343–347
doi: 10.1039/b202063g
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
